Answers are grounded in this paper and cite their sources.
Retrospective study reveals moderate accuracy of Cyfra 21-1 and CEA for NSCLC diagnosis, suggesting potential for precise biomarker application.
Introduction: Non-small cell lung cancer (NSCLC), a leading cause of cancer mortality, is often diagnosed late, necessitating reliable biomarkers. Carcinoembryonic Antigen (CEA) and Cytokeratin 19 Fragment (CYFRA 21-1) show promise for early detection and prognosis in NSCLC, but their performance requires further validation. Methods: This retrospective study evaluated 135 patients at a tertiary hospital for lung cancer. Diagnostic performance of CEA and CYFRA 21-1 was assessed via Receiver Operating Characteristic (ROC) analysis, with subgroup analyses across histological subtypes. Survival was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Results: Of 135 patients, 95 had NSCLC (70.4%). ROC analysis showed moderate diagnostic accuracy for CEA (AUC: 0.78, 95% CI: 0.70–0.85; cut-off: 5.5 ng/mL, sensitivity: 72%, specificity: 68%) and CYFRA 21-1 (AUC: 0.82, 95% CI: 0.75–0.88; cut-off: 3.8 ng/mL, sensitivity: 78%, specificity: 70%). Subgroup analysis revealed CYFRA 21-1’s superior accuracy in squamous cell carcinoma (AUC: 0.87, sensitivity: 82%, specificity: 75%) and adenocarcinoma (AUC: 0.84), while CEA performed better in poorly differentiated carcinoma (AUC: 0.77). Elevated CEA (>5.5 ng/mL) and CYFRA 21-1 (>3.8 ng/mL) predicted worse survival (HR: 1.5, 95% CI: 1.1–2.0; HR: 1.7, 95% CI: 1.2–2.3), reducing median survival to 12 and 10 months from 20 and 22 months, respectively. Conclusion: CEA and CYFRA 21-1 enhance NSCLC diagnosis and prognosis, with histology-specific strengths, supporting their role in precision oncology.
No takes yet. Share an insight, caveat, or question.
Vo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: